Registered title, quoted from ClinicalTrials.gov
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
An open trial on idiopathic pulmonary fibrosis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 12 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 12
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Inner Mongolia Medical University内蒙古医科大学附属医院HohhotHospital page
- Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
- Study siteDongfang Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteHangzhou First People's Hospital杭州市第一人民医院HangzhouHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteHuadong Hospital, Fudan University复旦大学附属华东医院ShanghaiHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
- Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
- Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
- Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07121413, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
40 years to Not stated; sex: all
Registered eligibility fields
Subjects must agree to use highly effective contraception during the study and for 6 months after the last administration of the study drug;
Inclusion criterion 2
History of malignancy within 5 years prior to screening;
Exclusion criterion 12
Positive pregnancy tests or currently lactating at screening;
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07121413, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subjects with a confirmed diagnosis of IPF and pulmonary function meeting the protocol-specified criteria;
- Subjects must agree to use highly effective contraception during the study and for 6 months after the last administration of the study drug;
- Subjucts must be able to understand the study, voluntarily provide written informed consent, and be willing and able to comply with all study-related procedures.
Exclusion Criteria:
- Subjects with a history of drug or other allergies, or those judged by the investigator to be potentially allergic to the study drugs;
- Presence of any other clinically significant pulmonary diseases besides IPF at screening;
- Any known contraindications to performing pulmonary function tests at screening;
- Respiratory or systemic infections requiring anti-infective therapy within 1 month prior to randomization;
- Acute exacerbation of IPF within 4 months prior to randomization;
- Use of any medication known to cause or worsen pulmonary fibrosis, as assessed by the investigator, within 3 months prior to screening;
- History of smoking within 3 months prior to screening, or unwillingness to quit smoking throughout the study period;
- Presence of clinically significant cardiovascular, cerebrovascular, hematological, neurological, psychiatric, or metabolic disease at screening, or plans for major surgery during the study period;
- Presence of specified abnormal laboratory test results at screening;
- Evidence of renal impairment or end-stage renal disease requiring dialysis at screening;
- Active hepatitis virus infection; history of acquired or congenital immunodeficiency disease;
- History of malignancy within 5 years prior to screening;
- Difficulty with venipuncture or a history of needle phobia or blood phobia;
- Positive pregnancy tests or currently lactating at screening;
- Participation in another clinical trial and receipt of other investigational drugs within 3 months prior to randomization;
- Any other condition that the investigator consider unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT07121413, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07121413, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.